Skip to main content
Jose Ochoa-Bayona, MD, Oncology, Tampa, FL, H. Lee Moffitt Cancer Center and Research Institute

JoseLeonelOchoa-BayonaMD

Oncology Tampa, FL

Assistant Professor, Oncologic Sciences, USF-Morsani

Overview of Dr. Ochoa-Bayona

Dr. Jose Ochoa-Bayona, MD is an oncologist in Tampa, Florida. He is currently licensed to practice medicine in Florida, California, and Puerto Rico. He is affiliated with H. Lee Moffitt Cancer Center and Research Institute.

Education & Training

  • University of Texas Health Science Center - San Antonio
    University of Texas Health Science Center - San AntonioFellowship, Hematology/Oncology, 1998 - 2001
  • University of Texas Health Science Center - San Antonio
    University of Texas Health Science Center - San AntonioResidency, Internal Medicine, 1995 - 1998
  • Universidad Autonoma de Nuevo Leon
    Universidad Autonoma de Nuevo LeonClass of 1989

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2021 - 2023
  • PR State Medical License
    PR State Medical License 2012 - 2022
  • FL State Medical License
    FL State Medical License 2007 - 2023
  • TX State Medical License
    TX State Medical License 2003 - 2022
  • LA State Medical License
    LA State Medical License 2001 - 2002
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • The Result of a Phase 1 Study of Selinexor in Combination with High-Dose Melphalan and Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
    Omar Alexis Castaneda Puglianini, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Panobinostat As a Maintenance Therapy after Autologous Hematopoietic Cell Transplantation for Patients with Multiple Myeloma
    Omar Alexis Castaneda Puglianini, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Elotuzumab in Combination with an Immunomodulatory Agent (IMID) in Patients with Multiple Myeloma Refractory to Imids and/or Daratumumab: A Single-Institution Analysis...
    Omar Alexis Castaneda Puglianini, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Grant Support

  • PH III Trial Of Melphalan And Prednisone W/ Or W/O Thalidomide For MMNational Center For Research Resources2005

Hospital Affiliations

Insurance Accepted

  • Aetna Choice POS II
    Aetna HMO
    Anthem Blue Access PPO
    Anthem Blue Preferred HMO
    AvMed Health Open Access
    BCBS Blue Card PPO
    BCBS Florida BlueCare HMO
    BCBS Florida NetworkBlue
    BCBS Florida Preferred Patient Care PPO
    BCBS Illinois PPO
    CIGNA HMO
    CIGNA Open Access
    CIGNA PPO
    Coventry Florida - Employer Group PPO
    First Health PPO
    Great West PPO
    Humana ChoiceCare Network PPO
    Kaiser Permanente
    Multiplan PHCS PPO
    Multiplan PPO
    Sagamore Health Plus
    United Healthcare - Direct Choice Plus POS
    United Healthcare - Direct Options PPO
  • Please verify your coverage with the provider's office directly when scheduling an appointment